News Releases

News Releases

August 6, 2020
MeiraGTx Reports Second Quarter 2020 Financial Results
- Positive initial data from Phase 1/2 clinical trial of AAV-RPGR for the treatment of XLRP recently presented - AAV-RPGR to advance into Phase 3 Lumeos clinical trial - Expands manufacturing capabilities with new facilities in Ireland LONDON and NEW YORK, Aug.
July 17, 2020
MeiraGTx Announces Positive Clinical Data Demonstrating Treatment with AAV-RPGR Investigational Gene Therapy Improves Vision in X-Linked Retinitis Pigmentosa Patients
• Data being presented at the American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting   • Significant improvements demonstrated after treatment in Phase 1/2 clinical trial   • Based on encouraging safety and efficacy profile, MeiraGTx and Janssen expect to progress AAV-RPGR into
May 7, 2020
MeiraGTx Reports First Quarter 2020 Financial Results
LONDON and NEW YORK, May 07, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the first quarter ended March 31, 2020 and provided an update on recent progress.
March 11, 2020
MeiraGTx Reports Full Year 2019 Financial Results
LONDON and NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the full year ended December 31, 2019 and provided an update on recent progress.
March 2, 2020
MeiraGTx Announces Priority Medicines (PRIME) and Advanced Therapy Medicinal Product (ATMP) Designations Granted by the European Medicines Agency to AAV-RPGR Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosa
PRIME designation granted based on clinical data from ongoing Phase 1/2 trial of AAV-RPGR AAV-RPGR is the only XLRP treatment in development to be awarded PRIME designation LONDON and NEW YORK, March 02, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc  (Nasdaq: MGTX), a vertically integrated,
February 24, 2020
MeiraGTx to Present at Upcoming Investor Conferences
LONDON and NEW YORK , Feb. 24, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes , Ph.D., president and chief executive officer, will present at the Cowen and Company 40th Annual Health